Core Viewpoint - The antitrust case involving dexamethasone raw material has concluded, resulting in significant fines for Jiangsu Lianhuan Pharmaceutical Co., Ltd. and its competitors, impacting their financial performance and future operations [1][2][4]. Group 1: Regulatory Actions and Financial Impact - Jiangsu Lianhuan Pharmaceutical was fined a total of 61.0382 million yuan, which represents 72.53% of its net profit for the previous year [3][4]. - The total fines imposed on the three companies involved in the price-fixing agreement amount to 326 million yuan [4]. - The fines include the confiscation of illegal gains of 17.8992 million yuan and an 8% penalty based on the company's 2023 sales [2][4]. Group 2: Financial Performance and R&D Investment - In 2024, Jiangsu Lianhuan reported a revenue of 2.16 billion yuan, a slight decrease of 0.63% year-on-year, and a net profit of 84.16 million yuan, down 37.66% from the previous year [6]. - The company has significantly increased its R&D investment, with expenses rising from 66 million yuan in 2021 to 155 million yuan in 2024, reflecting a compound annual growth rate of over 51% [7][8]. - The increase in R&D spending has pressured profit margins, leading to a decline in net profit despite revenue growth [7][8]. Group 3: Market Position and Competitive Landscape - Dexamethasone phosphate sodium is included in the treatment guidelines for severe COVID-19 patients, highlighting its importance in the pharmaceutical market [3]. - The company is shifting focus towards high-end formulations and innovative drugs, including projects targeting cancer and Alzheimer's disease [7][8]. - The innovative drug LH-1801, currently in phase III clinical trials, faces competition from several similar products already on the market [9].

Group 1 - The hair medical concept sector increased by 2.02%, ranking first among concept sectors, with 16 stocks rising, including Kanghui Pharmaceutical, Huailong Co., and *ST Jinbi reaching the daily limit [1][2] - Notable gainers in the sector included Kangyuan Pharmaceutical, which rose by 5.64%, *ST Meigu by 2.47%, and Shuiyang Co. by 2.33% [1][2] - The sector experienced a net outflow of 2.26 million yuan in main funds, with 10 stocks seeing net inflows, led by Huailong Co. with a net inflow of 110 million yuan [2][3] Group 2 - The top stocks by net inflow ratio included *ST Jinbi at 88.99%, Kanghui Pharmaceutical at 37.93%, and Huabang Health at 10.29% [3][4] - The hair medical concept sector's inflow list showed Huailong Co. with a daily increase of 10.01% and a turnover rate of 22.30%, while Kanghui Pharmaceutical had a daily increase of 10.02% with a turnover rate of 1.54% [3][4] - Other notable stocks included Aoyang Health with a 1.76% increase and a turnover rate of 29.93%, and Langzi Co. with a 1.61% increase and a turnover rate of 9.24% [3][4]

Core Viewpoint - The raw material pharmaceutical sector is under increased regulatory scrutiny due to antitrust actions, with Lianhuan Pharmaceutical facing significant penalties for price manipulation of Dexamethasone Sodium Phosphate, impacting its financial performance and growth prospects [2][9][12]. Regulatory Actions - Lianhuan Pharmaceutical received an administrative penalty from the Tianjin Market Supervision Administration for participating in a price-fixing agreement, resulting in a total fine of 61.0382 million yuan [2][7]. - The fine represents 72.53% of the company's net profit for the last fiscal year, exacerbating its ongoing financial struggles [9][10]. Financial Impact - The penalty includes the confiscation of illegal gains amounting to 17.8992 million yuan and a fine based on 8% of the company's 2023 sales, which was reduced by 30% due to mitigating circumstances [7][9]. - Lianhuan Pharmaceutical's revenue and net profit have been declining for two consecutive years, with projected revenues of approximately 1.955 billion yuan, 2.174 billion yuan, and 2.16 billion yuan from 2022 to 2024, and corresponding net profits of 141 million yuan, 135 million yuan, and 84 million yuan [10][11]. Company Response - Following the incident, Lianhuan Pharmaceutical has taken steps to comply with antitrust regulations, including terminating improper practices and enhancing its compliance management system [8][12]. - The company has also faced challenges in raising capital, with two planned financing efforts being aborted, leading to a shift towards debt financing for its R&D projects [13][14]. Market Context - The case reflects a broader trend of intensified antitrust enforcement in China, particularly in the pharmaceutical sector, aimed at maintaining fair competition and protecting consumer interests [12].

Group 1 - The State Financial Supervision Administration and seven other departments issued measures to support financing for small and micro enterprises, emphasizing the establishment of a coordination mechanism for financing support [1] - The measures include conducting extensive visits to small and micro enterprises to assess their operational status and financing needs, facilitating direct access to bank credit [1] - There is a focus on addressing the operational difficulties faced by small and micro enterprises and encouraging support for key sectors such as foreign trade, private enterprises, technology, and consumption [1] Group 2 - In May 2025, a total of 130 domestic online games were approved by the National Press and Publication Administration [2] Group 3 - The State Council announced the removal of Wang Jianjun from the position of Vice Chairman of the China Securities Regulatory Commission [3] Group 4 - The Shanghai Municipal Government issued a plan to boost consumption, which includes measures to promote reasonable income growth and improve wage distribution mechanisms [4] - The plan aims to enhance the minimum wage adjustment mechanism and support the development of the rural economy and new business models [4] Group 5 - Shanghai is accelerating the introduction of childcare subsidies and maternity social security subsidies as part of its efforts to build a family-friendly society [5] - The city plans to explore increasing parental leave and spouse's paternity leave while enhancing the quality of public kindergartens [5] Group 6 - The Ministry of Foreign Affairs stated that China has the capability and confidence to handle external risks, including tariff wars, as evidenced by a 2.4% year-on-year increase in total goods import and export in the first four months of the year [6] - Exports grew by 7.5%, indicating strong international competitiveness despite high tariff barriers [6] Group 7 - The Ministry of Foreign Affairs expressed strong opposition to the EU's unilateral sanctions against Chinese companies, emphasizing the need for fair trade practices [8] - The ministry highlighted that normal business interactions between Chinese and Russian companies should not be disrupted by these sanctions [8] Group 8 - The Dalian Commodity Exchange announced trading arrangements for the Dragon Boat Festival period, with a market closure from May 31 to June 2, 2025, and a return to normal trading on June 3 [9] Group 9 - Heng Rui Pharmaceutical set the issuance price for its H-shares at HKD 44.05 per share [11] - Xinyuan Technology plans to issue H-shares and list on the Hong Kong Stock Exchange [11] - The company Guokai Microelectronics is planning a major asset restructuring, leading to a suspension of its stock from May 22 [11]

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

浙江仙琚制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的关于黄体酮软胶囊的《药品注册证书》（证书编号：2025S01275、 2025S01276），公司黄体酮软胶囊被批准注册。现将相关情况公告如下： 申请内容：境内生产药品注册上市许可。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品的其他相关情况 黄体酮软胶囊，规格为0.1g和0.2g，参比制剂为原研进口的黄体酮软胶囊， 商品名：安琪坦®（Utrogestan®）。该参比制剂由比利时Besins Healthcare开发， 0.1g规格于1981年9月在比利时批准上市，0.2g规格于2006年1月在比利时批准上 市。1992年10月，安琪坦®0.1g规格在中国获批进口，2013年5月，安琪坦®0.2g 规格在中国获批进口。黄体酮软胶囊的适应症为用于黄体缺乏引起的机能障碍， 有助于妊娠。Besins Healthcare的黄体酮软胶囊已在荷兰、法国、英国、瑞士、 1 证券代码：002332 证券简称：仙琚制药 公告编号：2025-026 浙江仙琚制 ...

Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. has announced its 2024 annual profit distribution plan, which includes a cash dividend of RMB 3.00 per 10 shares for all shareholders, approved at the shareholders' meeting on May 15, 2025 [1][2]. Summary by Sections Shareholder Meeting Approval - The profit distribution plan was approved at the 2025 annual shareholders' meeting, with a total share capital of 989,204,866 shares as of December 31, 2024 [1]. Dividend Distribution Details - The company will distribute a cash dividend of RMB 3.00 per 10 shares (before tax) to all shareholders. For specific categories of investors, the net dividend will be RMB 2.70 per 10 shares after tax deductions [1]. - Different tax rates apply for various types of shareholders, with specific provisions for those holding shares before and after the initial public offering [1]. Key Dates - The record date for the dividend distribution is set for May 27, 2025, and the ex-dividend date is May 28, 2025 [1]. Dividend Payment Method - The cash dividends will be directly credited to the shareholders' accounts through their securities companies or other custodial institutions [2]. Contact Information - For inquiries, shareholders can contact the company at its office in Zhejiang Province, with a designated contact person and phone number provided [2].

股票代码：002332 股票简称：仙琚制药 公告编号：2025-025 浙江仙琚制药股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"或"本公司"）2024 年年 度权益分派方案已获 2025 年 5 月 15 日召开的公司 2024 年年度股东大会审议通 过，现将权益分派事宜公告如下： 3、本次实施的利润分配方案与公司 2024 年度股东大会审议通过的分配方 案一致。 4、本次实施的利润分配方案距公司 2024 年度股东大会审议通过的时间未 超过两个月。 二、本次权益分派方案 本公司 2024 年年度权益分派方案为：以公司现有总股本 989,204,866 股为 基数，向全体股东每 10 股派发现金红利人民币 3.00 元（含税；扣税后，通过 深股通持有股份的香港市场投资者、QFII、RQFII 以及持有首发前限售股的个 人和证券投资基金每 10 股派 2.70 元；持有首发后限售股、股权激励限售股及 无限售流通股的个人股息红利税实行差别化税率征收，本公司暂不扣缴个人所 ...

Core Viewpoint - The enforcement of antitrust laws in China has expanded to hold individuals accountable for organizing monopolistic agreements, marking a significant shift in regulatory practices and emphasizing the importance of compliance in sensitive industries like pharmaceuticals and energy [1][4][15] Summary by Sections Case Overview and Harm of Monopolistic Agreements - Four pharmaceutical companies were penalized for reaching a monopolistic agreement to fix prices of dexamethasone phosphate sodium raw materials, violating Article 17 of the Antitrust Law [2] - The individual responsible, identified as Guo, was fined 5 million yuan for facilitating this agreement, which is significant as it is the first case post-2022 Antitrust Law revision to hold an individual accountable [2][3] Market Impact and Social Consequences - The monopolistic behavior led to a significant distortion of market competition, affecting the pricing of downstream pharmaceutical products and increasing the financial burden on patients and the national healthcare system [3][4] - The raw material in question is crucial for producing medications used in treating severe COVID-19 cases, highlighting the public health implications of such monopolistic practices [2][3] Enforcement Highlights - This case represents a landmark in antitrust enforcement, as it extends liability to individuals who organize monopolistic agreements, thereby enhancing the legal accountability of market participants [4][6] - The enforcement action against Guo illustrates a shift towards a more comprehensive regulatory approach that targets not just corporate entities but also the individuals orchestrating anti-competitive behavior [4][8] Legal Framework and Implications - The 2022 revision of the Antitrust Law introduced provisions that explicitly prohibit individuals from organizing or assisting in the formation of monopolistic agreements, addressing previous regulatory gaps [9][10] - The case against Guo serves as a critical example of the legal system's ability to adapt and respond to complex market dynamics, particularly in the context of digital economies where traditional enforcement may be challenged [11][12] Economic Perspective - The role of organizers in monopolistic agreements is crucial, as they can significantly lower the costs of collusion and enhance the stability of such agreements, thereby posing a serious threat to market competition [10][11] - By targeting the organizers, the regulatory framework aims to prevent the formation of monopolistic structures before they can cause substantial market harm [11][15]

7月24日，创新药盘中崛起，截止发稿，A股方面，三生国健、百利天恒涨超7%，海思科、诺诚健华、仙琚制药涨超4%，科伦制药、通化东宝等跟涨。 | 代码 名称 | 涨幅 | 消费 | 现价 | | --- | --- | --- | --- | | 000908 景峰医药 | +10.12% | +0.26 | 2.83 | | 688336 三生国健 | +7.66% | +1.38 | 19.26 | | 688506 自利大恒-U | +6.80% | +5.51 | 86.51 | | 688305 海外交 - U | +5.86% | +2.84 | 51.29 | | 688658 倪康药业 | +4.63% | +0.80 | 18.09 | | 002653 海器科 | +4.63% | +1.02 | 23.07 | | 688428 诺诚健华-U | +4.17% | +0.48 | 11.99 | | 603567 珍宝岛 | +4.09% | +0.57 | 14.26 | | 002332 仙琚制药 | +4.01% | +0.50 | 12.97 | | 600276 恒瑞 名 | + ...